These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 17286185)

  • 1. Rapid regression of extensive retinovitreal neovascularization secondary to branch retinal vein occlusion after a single intravitreal injection of bevacizumab.
    Ahmadieh H; Moradian S; Malihi M
    Int Ophthalmol; 2005; 26(4-5):191-3. PubMed ID: 17286185
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Rapid improvement of retinal and iris neovascularization after a single intravitreal bevacizumab injection in a patient with central retinal vein occlusion and neovascular glaucoma.
    Batioğlu F; Astam N; Ozmert E
    Int Ophthalmol; 2008 Feb; 28(1):59-61. PubMed ID: 17609852
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Intravitreal bevacizumab (Avastin) as a treatment of the neovascular complications of laser-induced chorioretinal anastomosis for nonischaemic central retinal vein occlusion.
    Fong KC; Barry C; McAllister IL
    Clin Exp Ophthalmol; 2009 Jul; 37(5):485-9. PubMed ID: 19624345
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Rapid regression of retinal neovascularization following intravitreal bevacizumab in branch retinal vein occlusion imaged by optical coherence tomography angiography.
    Brar M; Grewal DS; Sharma M; Grewal SPS
    Indian J Ophthalmol; 2018 Apr; 66(4):572. PubMed ID: 29582824
    [No Abstract]   [Full Text] [Related]  

  • 5. Intravitreal bevacizumab (Avastin) in the treatment of proliferative diabetic retinopathy.
    Avery RL; Pearlman J; Pieramici DJ; Rabena MD; Castellarin AA; Nasir MA; Giust MJ; Wendel R; Patel A
    Ophthalmology; 2006 Oct; 113(10):1695.e1-15. PubMed ID: 17011951
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Intravitreal injection of bevacizumab for macular edema secondary to branch retinal vein occlusion:results after 12 months and multiple regression analysis.
    Kondo M; Kondo N; Ito Y; Kachi S; Kikuchi M; Yasuma TR; Ota I; Kensaku M; Terasaki H
    Retina; 2009 Oct; 29(9):1242-8. PubMed ID: 19672216
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Combined intravitreal bevacizumab and triamcinolone injection in a child with Coats disease.
    Cakir M; Cekiç O; Yilmaz OF
    J AAPOS; 2008 Jun; 12(3):309-11. PubMed ID: 18589387
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of two doses of intravitreal bevacizumab (Avastin) for treatment of macular edema secondary to branch retinal vein occlusion: results from the Pan-American Collaborative Retina Study Group at 6 months of follow-up.
    Wu L; Arevalo JF; Roca JA; Maia M; Berrocal MH; Rodriguez FJ; Evans T; Costa RA; Cardillo J;
    Retina; 2008 Feb; 28(2):212-9. PubMed ID: 18301025
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The effects of intravitreal bevacizumab on patients with macular edema secondary to branch retinal vein occlusion.
    Ahmadi AA; Chuo JY; Banashkevich A; Ma PE; Maberley DA
    Can J Ophthalmol; 2009 Apr; 44(2):154-9. PubMed ID: 19491948
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Intravitreal bevacizumab (Avastin) for subretinal neovascularization secondary to type 2A idiopathic juxtafoveal telangiectasia.
    Mandal S; Venkatesh P; Abbas Z; Vohra R; Garg S
    Graefes Arch Clin Exp Ophthalmol; 2007 Dec; 245(12):1825-9. PubMed ID: 17345090
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical, anatomic, and electrophysiologic evaluation following intravitreal bevacizumab for macular edema in retinal vein occlusion.
    Pai SA; Shetty R; Vijayan PB; Venkatasubramaniam G; Yadav NK; Shetty BK; Babu RB; Narayana KM
    Am J Ophthalmol; 2007 Apr; 143(4):601-6. PubMed ID: 17306753
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of multiple injections of small divided doses vs single injection of intravitreal bevacizumab on retinal neovascular model in rabbits.
    Saati S; Agrawal RN; Louie S; Chader GJ; Humayun MS
    Graefes Arch Clin Exp Ophthalmol; 2010 Apr; 248(4):457-66. PubMed ID: 19644699
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Early intravitreal bevacizumab for non-ischaemic central retinal vein occlusion.
    Rensch F; Jonas JB; Spandau UH
    Acta Ophthalmol; 2009 Feb; 87(1):77-81. PubMed ID: 18937800
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Intravitreal bevacizumab for treatment of neovascular glaucoma. Report of 20 cases].
    Douat J; Auriol S; Mahieu-Durringer L; Ancèle E; Pagot-Mathis V; Mathis A
    J Fr Ophtalmol; 2009 Nov; 32(9):652-63. PubMed ID: 19892433
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Intravitreal bevacizumab (Avastin) associated with the regression of subretinal neovascularization in idiopathic juxtafoveolar retinal telangiectasis.
    Jorge R; Costa RA; Calucci D; Scott IU
    Graefes Arch Clin Exp Ophthalmol; 2007 Jul; 245(7):1045-8. PubMed ID: 17136357
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Repeated intravitreal bevacizumab (Avastin(®)) treatment of persistent new vessels in proliferative diabetic retinopathy after complete panretinal photocoagulation.
    Schmidinger G; Maar N; Bolz M; Scholda C; Schmidt-Erfurth U
    Acta Ophthalmol; 2011 Feb; 89(1):76-81. PubMed ID: 21272288
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Intravitreal bevacizumab (avastin) in the treatment of macular edema associated with perfused retinal vein occlusion.
    Hung KH; Lee SM; Lee SY; Lee FL; Yang CS
    J Ocul Pharmacol Ther; 2010 Feb; 26(1):85-90. PubMed ID: 20148661
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Use of intravitreal bevacizumab for macular edema in branch retinal vein occlusion].
    Yamauchi Y; Mori F; Masahara H; Kameda Y; Suzuki M; Mori Y; Eguchi S
    Nippon Ganka Gakkai Zasshi; 2009 Jun; 113(6):672-4. PubMed ID: 19606809
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Intravitreal bevacizumab injections for treatment of central retinal vein occlusion: six-month results of a prospective trial.
    Priglinger SG; Wolf AH; Kreutzer TC; Kook D; Hofer A; Strauss RW; Alge CS; Kunze C; Haritoglou C; Kampik A
    Retina; 2007 Oct; 27(8):1004-12. PubMed ID: 18040236
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Intravitreal bevacizumab (Avastin) in the treatment of macular edema secondary to branch retinal vein occlusion.
    Rabena MD; Pieramici DJ; Castellarin AA; Nasir MA; Avery RL
    Retina; 2007; 27(4):419-25. PubMed ID: 17420692
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.